Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.
Michael Y HeKensuke KayamoriPublished in: British journal of haematology (2023)
In this issue, Rovsing et al. employ unbiased genome-wide CRISPR screening and functional cellular assays to investigate the cellular response to vincristine, an important component of the front-line DLBCL treatment R-CHOP. Their findings reveal intriguing targets and mechanisms that hold promise for enhancing DLBCL treatment and provide a foundation for the development of future drug regimens. This research prompts further exploration of the translational potential to advance more effective and individualized approaches in the clinical management of DLBCL. Commentary on: Rovsing et al. Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. Br J Haematol 2023 (Online ahead of print). doi:10.1111/bjh.18872.
Keyphrases
- genome wide
- diffuse large b cell lymphoma
- cell cycle arrest
- dna methylation
- cell death
- copy number
- pi k akt
- genome editing
- machine learning
- oxidative stress
- gene expression
- healthcare
- high glucose
- combination therapy
- crispr cas
- high throughput
- endothelial cells
- signaling pathway
- social media
- artificial intelligence
- current status
- stress induced
- deep learning